0001493152-17-012317.txt : 20171102 0001493152-17-012317.hdr.sgml : 20171102 20171102112536 ACCESSION NUMBER: 0001493152-17-012317 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20171102 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20171102 DATE AS OF CHANGE: 20171102 FILER: COMPANY DATA: COMPANY CONFORMED NAME: VBI Vaccines Inc/BC CENTRAL INDEX KEY: 0000764195 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: A1 FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37769 FILM NUMBER: 171171266 BUSINESS ADDRESS: STREET 1: 222 THIRD STREET STREET 2: SUITE 2241 CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617-830-3031 MAIL ADDRESS: STREET 1: 222 THIRD STREET STREET 2: SUITE 2241 CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: SciVac Therapeutics Inc. DATE OF NAME CHANGE: 20150717 FORMER COMPANY: FORMER CONFORMED NAME: LEVON RESOURCES LTD. DATE OF NAME CHANGE: 20100910 FORMER COMPANY: FORMER CONFORMED NAME: LEVON RESOURCES LTD DATE OF NAME CHANGE: 19850305 8-K 1 form8-k.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported): November 2, 2017

VBI VACCINES INC.

(Exact name of registrant as specified in its charter)

British Columbia, Canada		001-37769		N/A
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

222 Third Street, Suite 2241

Cambridge, Massachusetts

02142

(Address of principal executive offices)

(Zip Code)

(617) 830-3031

(Registrant’s telephone number, including area code)

N/A

(Former Name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[ ]	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[ ]	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[ ]	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[ ]	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company [X]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [X]

Item 8.01 Other Events.

On November 2, 2017, VBI Vaccines Inc. (the “Company”) issued a press release announcing the appointment, effective as of October 30, 2017, of Ran Nussbaum, co-founder and managing partner of The Pontifax Group, to the Company’s board of directors. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is hereby incorporated by reference herein.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No		Description

99.1		Press Release dated November 2, 2017

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	VBI Vaccines Inc.

Date: November 2, 2017	By:	/s/ Jeff Baxter
		Jeff Baxter
		President and Chief Executive Officer

EX-99.1 2 ex99-1.htm

VBI Vaccines Strengthens Board of Directors with Appointment of Ran Nussbaum

	●	Ran Nussbaum, managing partner and co-founder of The Pontifax Group, joins VBI Board of Directors
	●	Pontifax’s participation in the recent financing was alongside investments from several new fundamental life sciences institutional funds and insiders, notably Perceptive Advisors
	●	This financing provides VBI with sufficient runway through headline data from the pivotal Phase III clinical program of the company’s Hepatitis B vaccine, Sci-B-Vac®

CAMBRIDGE, Mass. (November 2, 2017) – VBI Vaccines Inc. (Nasdaq: VBIV) (TSX: VBV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced the appointment, effective October 30, 2017, of Ran Nussbaum, co-founder and managing partner of The Pontifax Group, to the company’s Board of Directors. Mr. Nussbaum’s appointment follows The Pontifax Group’s investment in VBI in its recently closed financing, which now provides the company with sufficient runway through headline data from the Sci-B-Vac® pivotal Phase III program for the prevention of Hepatitis B.

“We are honored to have Ran join our Board of Directors,” said Jeff Baxter, VBI’s president and CEO. “Pontifax’s participation in this financing and Ran’s appointment to our Board further progresses our relationship with Israeli strategic investors, represented by Pontifax. Ran will bring a proven track record of broad life sciences business experience, most recently as a founding Board member of Kite Pharma. Alongside the existing expertise on the Board, Ran’s appointment will strengthen VBI’s dynamic and well-rounded Board of Directors.”

“With the upcoming initiation of the Phase III program for Sci-B-Vac^®, and continued clinical development of VBI’s pipeline programs, I’m excited to be joining the Board of VBI at such a pivotal time,” said Ran Nussbaum. “I look forward to working with Jeff and the rest of the VBI team and Board.”

The Pontifax Group is a life sciences venture capital firm with an extensive global portfolio focused on unmet needs within the healthcare industry. Prior to joining Pontifax, Mr. Nussbaum was a partner at Israel’s largest business intelligence and strategic consulting firm. Mr. Nussbaum serves, or has served, as a board member on many of Pontifax’s portfolio companies, including Kite Pharma, Keros (as chairman), UroGen Ltd, cCam Biotherapeutics (bought by Merck), Eloxx Pharmaceuticals, and NovellusDX.

About VBI Vaccines Inc.

VBI Vaccines Inc. (“VBI”) is a commercial-stage biopharmaceutical company developing a next generation of vaccines to address unmet needs in infectious disease and immuno-oncology. VBI’s first marketed product is Sci-B-Vac™, a hepatitis B (HBV) vaccine that mimics all three viral surface antigens of the hepatitis B virus; Sci-B-Vac is approved for use in Israel and 14 other countries. VBI’s eVLP Platform technology allows for the development of enveloped virus-like particle (eVLP) vaccines that closely mimic the target virus to elicit a potent immune response. VBI is advancing a pipeline of eVLP vaccines, with lead programs in cytomegalovirus (CMV) and glioblastoma multiforme (GBM). VBI is also advancing its LPV™ Thermostability Platform, a proprietary formulation and process that enables vaccines and biologics to preserve stability, potency, and safety. VBI is headquartered in Cambridge, MA with research operations in Ottawa, Canada and research and manufacturing facilities in Rehovot, Israel.

	●	Website Home: http://www.vbivaccines.com/
	●	News and Insights: http://www.vbivaccines.com/wire/
	●	Investors: http://www.vbivaccines.com/investors/

Cautionary Statement on Forward-looking Information

Certain statements in this press release that are forward-looking and not statements of historical fact are forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and are forward-looking information within the meaning of Canadian securities laws (collectively “forward-looking statements”). The company cautions that such statements involve risks and uncertainties that may materially affect the company’s results of operations. Such forward-looking statements are based on the beliefs of management as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including but not limited to the ability to establish that potential products are efficacious or safe in preclinical or clinical trials; the ability to establish or maintain collaborations on the development of therapeutic candidates; the ability to obtain appropriate or necessary governmental approvals to market potential products; the ability to obtain future funding for developmental products and working capital and to obtain such funding on commercially reasonable terms; the company’s ability to manufacture product candidates on a commercial scale or in collaborations with third parties; changes in the size and nature of competitors; the ability to retain key executives and scientists; and the ability to secure and enforce legal rights related to the company’s products, including patent protection. A discussion of these and other factors, including risks and uncertainties with respect to the company, is set forth in the Company’s filings with the Securities and Exchange Commission and the Canadian securities authorities, including its Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 20, 2017, and filed with the Canadian security authorities at sedar.com on March 24, 2017, as may be supplemented or amended by the Company’s Quarterly Reports on Form 10-Q. The company disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

VBI Contact

Nicole Anderson, Communications Executive

Phone: (617) 830-3031 x124

Email: info@vbivaccines.com

VBI Investor Contact

Nell Beattie, Chief Business Officer

Phone: (617) 830-3031 x128

Email: IR@vbivaccines.com

VBI Media Contact

Matt Middleman, M.D.

LifeSci Public Relations

Phone: (646) 627-8384

Email: matt@lifescipublicrelations.com

GRAPHIC 3 ex99-1_001.jpg begin 644 ex99-1_001.jpg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end